• Alkomiet Hasan, Peter Falkai, Isabell Lehmann, and Wolfgang Gaebel.
• Department of Psychiatry, Psychotherapy, and Psychosomatics, Faculty of Medicine, University ofAugsburg, District Hospital Augsburg, AugsburgDepartment of Psychiatry and Psychotherapy, LMU Medical Center, MunichLVR Institute for Health Care Research, CologneDepartment of Psychiatry and Psychotherapy, LVR Hospital Düsseldorf, Faculty of Medicine,University of Düsseldorf.
• Dtsch Arztebl Int. 2020 Jun 12; 117 (24): 412419412-419.

BackgroundThe lifetime prevalence of schizophrenia is 1%. Schizophrenia is among the most severe mental illnesses and gives rise to the highest treatment costs per patient of any disease. It is characterized by frequent relapses, marked impairment of quality of life, and reduced social and work participation.MethodsThe group entrusted with the creation of the German clinical practice guideline was chosen to be representative and pluralistic in its composition. It carried out a systematic review of the relevant literature up to March 2018 and identified a total of 13 389 publications, five source guidelines, three other relevant German clinical practice guidelines, and four reference guidelines.ResultsAs the available antipsychotic drugs do not differ to any great extent in efficacy, it is recommended that acute antipsychotic drug therapy should be sideeffect- driven, with a number needed to treat (NNT) of 5 to 8. The choice of treatment should take motor, metabolic, sexual, cardiac, and hematopoietic considerations into account. Ongoing antipsychotic treatment is recommended to prevent relapses (NNT: 3) and should be re-evaluated on a regular basis in every case. It is also recommended, with recommendation grades ranging from strong to intermediate, that disorder- and manifestation-driven forms of psychotherapy and psychosocial therapy, such as cognitive behavioral therapy for positive or negative manifestations (effect sizes ranging from d = 0.372 to d = 0.437) or psycho-education to prevent relapses (NNT: 9), should be used in combination with antipsychotic drug treatment. Further aspects include rehabilitation, the management of special treatment situations, care coordination, and quality management. A large body of evidence is available to provide a basis for guideline recommendations, particularly in the areas of pharmacotherapy and cognitive behavioral therapy.ConclusionThe evidence-based diagnosis and treatment of persons with schizophrenia should be carried out in a multiprofessional process, with close involvement of the affected persons and the people closest to them.

8 keywords...

hide…